Cargando…

YAP regulates PD-L1 expression in human NSCLC cells

Programmed death-ligand 1 (PD-L1) is a membrane protein on tumor cells that binds to the PD-1 receptor expressed on immune cells, leading to the immune escape of tumor cells. Yes-associated protein (YAP) is a main effector of the Hippo/YAP signaling pathway, which plays important roles in cancer dev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miao, Jinbai, Hsu, Ping-Chih, Yang, Yi-Lin, Xu, Zhidong, Dai, Yuyuan, Wang, Yucheng, Chan, Geraldine, Huang, Zhen, Hu, Bin, Li, Hui, Jablons, David M., You, Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777715/ https://www.ncbi.nlm.nih.gov/pubmed/29383103 http://dx.doi.org/10.18632/oncotarget.23051

Ejemplares similares

Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells
por: You, Bin, et al.
Publicado: (2015)

A novel isoform of Homeodomain-interacting protein kinase-2 promotes YAP/TEAD transcriptional activity in NSCLC cells
por: Dai, Yuyuan, et al.
Publicado: (2021)

Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
por: Hsu, Ping-Chih, et al.
Publicado: (2019)

The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC)
por: Hsu, Ping-Chih, et al.
Publicado: (2020)

The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer
por: Hsu, Ping-Chih, et al.
Publicado: (2018)

Inhibition of yes‐associated protein down‐regulates PD‐L1 (CD274) expression in human malignant pleural mesothelioma
por: Hsu, Ping‐Chih, et al.
Publicado: (2018)

Inhibition of yes‐associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model
por: Hsu, Ping‐Chih, et al.
Publicado: (2018)

YAP promotes erlotinib resistance in human non-small cell lung cancer cells
por: Hsu, Ping-Chih, et al.
Publicado: (2016)

YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells
por: Dai, Yuyuan, et al.
Publicado: (2016)

Targeting YAP in malignant pleural mesothelioma
por: Zhang, Wen‐Qian, et al.
Publicado: (2017)

Inhibition of cyclin‐dependent kinase 7 down‐regulates yes‐associated protein expression in mesothelioma cells
por: Miao, Jinbai, et al.
Publicado: (2019)

CK2α, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells
por: Zhang, Shulin, et al.
Publicado: (2014)

Repression of YAP by NCTD disrupts NSCLC progression
por: Guo, Jiwei, et al.
Publicado: (2016)

Targeting YAP/TAZ in Combination with PD-L1 Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC)
por: Papavassiliou, Kostas A., et al.
Publicado: (2023)

Cul4A overexpression associated with Gli1 expression in malignant pleural mesothelioma
por: Yang, Yi-Lin, et al.
Publicado: (2015)

Various impacts of driver mutations on the PD-L1 expression of NSCLC
por: Chu, Cheng-Hsiang, et al.
Publicado: (2022)

The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC
por: Jin, Dan, et al.
Publicado: (2018)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
por: Zhang, Jie, et al.
Publicado: (2015)

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
por: Chang, Gee-Chen, et al.
Publicado: (2020)

Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis
por: Jin, Dan, et al.
Publicado: (2020)

Radiotherapy combined with PD‐1/PD‐L1 inhibitors in NSCLC brain metastases treatment: The mechanisms, advances, opportunities, and challenges
por: Chen, Zi‐Ying, et al.
Publicado: (2022)

Correction: Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis
por: Jin, Dan, et al.
Publicado: (2022)

YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC
por: Ghiso, Elena, et al.
Publicado: (2017)

PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC
por: Wu, Chiao-En, et al.
Publicado: (2020)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
por: Janning, Melanie, et al.
Publicado: (2019)

Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients
por: Li, Chuling, et al.
Publicado: (2019)

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
por: Schmidt, Lars Henning, et al.
Publicado: (2015)

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
por: Brogden, Kim A., et al.
Publicado: (2018)

m(6)A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2–mediated YAP activity in NSCLC
por: Jin, Dan, et al.
Publicado: (2020)

PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC
por: Ameratunga, Malaka, et al.
Publicado: (2016)

Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC
por: Gauvin, Camille, et al.
Publicado: (2021)

Correction: m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2–mediated YAP activity in NSCLC
por: Jin, Dan, et al.
Publicado: (2022)

Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression
por: Lin, Ziying, et al.
Publicado: (2019)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022)

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
por: Masuda, Ken, et al.
Publicado: (2020)

Inflammatory and autoimmune predictive markers of response to anti-PD-1/PD-L1 therapy in NSCLC and melanoma
por: Musaelyan, Aram A., et al.
Publicado: (2022)

Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
por: Brogden, Kim A., et al.
Publicado: (2018)

TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC)
por: Cao, Xiaobo, et al.
Publicado: (2017)

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
por: Kowanetz, Marcin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7fidkdlijuaof3910d8hso06sf